New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs

(MedPage Today) — No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ panel.
In a new “living” guideline…